Work

150P Single-institutional real-world data of nirogacestat for refractory, symptomatic desmoid tumor patients: Initial dosing strategy, first-month adverse event management, and patient-reported symptom improvement

Year: 2025

Type: article

Abstract: Nirogacestat is a promising therapy for desmoid tumors (DT) with EMA approval under evaluation. Our study aims to provide real-world data from a single institution on the initial dosing strategy, first-month management of adverse events (AEs), and early patient-reported outcome.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2025.104463

Authors: P.H. Viveiros, S. Orlando, N. Bilani, M.F. Silva Almeida Ribeiro, J.D. Wayne, S. Pollack

Institutions: Northwestern University, Campus Bio Medico University Hospital, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Moffitt Cancer Center

Language: English

Topic: Soft tissue tumor case studies

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,910